Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drug

Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a protein that plays a role in regulating a number of inflammatory processes that are believed to contribute to the damage to brain cells that underlies Parkinson’s.

Local healthcare options lead to better outcomes for the elderly

Older people with health problems often need some form of intermediate level monitoring, care and treatment services.

June 22, 2023

New program offers hiking adventures for people with younger-onset Alzheimer’s

Starting this July, people diagnosed with Alzheimer’s before age 65 will have a new opportunity to connect with others while exploring the great outdoors through

July 8, 2023

Better prevention and treatment options needed for genital herpes, WHO says – Pharmaceutical Technology

There is currently no cure for genital herpes, though medication can control the infection. Image credit: Shutterstock / Richard Juilliart. A World Health Organization (WHO)

December 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.